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WATCHFUL WAITING FOR ELDERLY PATIENTS 
WITH LOCALIZED PROST A TE CANCER 
Osamu MAEDA， Ken-ichi KAKIMOTO， Yutaka ONO， 
Norio MEGURO， Toshiaki KINOUCHI and Michiyuki USAMI 
The Department 01 Urology， Osaka Medical Center 10r Ca仰 rand Cardiovascular Diseωes 
Watchful-waiting policy is an important treatment option for some patients with localized prostate 
cancer and it is widely recognized in Western countries in which the prostate cancer mortality rate is 5-
10 fold higher than that in]apan. Most men with well and perhaps moderately differentiated prostate 
cancer who have a life expectancy ofless than 10 years will die of other causes and it is not clear whether 
early primary hormone therapy improves survival and the quality of life compared to androgen 
suppression deferred until signs and symptoms of clinical progression. There is 0町 majorquestion as 
to whether patients who do not need radical treatment should undergo early primary hormone therapy 
in ]apan in spite of high cost and treatment-related adverse effects of hormone therapy. 
(Hi町okikaKiyo 51 : 561-563， 2005) 






































expected survival rate for 75巳.year世oldJapanese men 
Fig. 1. Results of conservative management of 
clinically localized prostate cancer ac“ 
cording to tumor grade (Chodak GW， et

















































Table 1. Immediate versus deferred hormonal 
therapy: Results of randomized trials. 
No. Actual Study Stage survival cases significance 
V ACURG study 13) 1903 Stage II & IV 
MRC4) 938 MO ・Ml
EORTC308467) 234 pNト3
~~\~) (adjuvant for 
RT)8) 401 r~-~ ， G3 or 0<0.0001 T3-4' p 
MesPsxin)E町 (adjuvant aι 
tcr 98 TI-2 pN1 p=0.02 





























均年齢72.1歳 (59-84)，臨床病期 Tlc36例， T2a 10 
例， T2b 2例， Gleason score 6以下 28例， 7 18例，
8 2例， PSAの中央値は 8.6ng/ml(1.4-21.2)で
あった. PSADTの中央値は60カ月， 24カ月未満の
rapid riserは6例(12.5%)であった.無治療待機療
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